FDA “Breakthrough” Designation Bill Revives Debate About Legislating Flexibility

FDA appears to support the idea behind the bipartisan bill, which would allow the agency to meet with the sponsor early in the development process when a candidate shows substantial improvement over existing therapies and consider expedited trials going forward.